Eduardo Bravo, formerly chief executive officer of TiGenix NV, has been named CEO of Nordic Nanovector ASA to oversee development of the Norwegian company’s oncology portfolio. Mr Bravo will be based in London, UK. As CEO of TiGenix, he successfully developed the company through several financing rounds leading to its acquisition by Takeda Pharmaceutical Co Ltd earlier this year. Mr Bravo is currently chairman of Vivet Therapeutics SAS, a French gene therapy company. He holds a degree in business administration and an MBA from the INSEAD Business School in France.
Nordic Nanovector announced the appointment on 25 June 2018.
Evernow Publishing Ltd 2018.